Allan Fernandez
Family Medicine · Binghamton, NYNPI 1144597527
Payments from drug & device makers
Across 226 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Gilead$538
- Braeburn Inc.$422
- Indivior Inc.$405
- Teva Pharmaceuticals USA, Inc.$348
- Exact Sciences$215
- plus $835 from 14 others
What the payments were for
- Food & beverage$4,84698%
- Education$822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 97 | $2,165 |
| Gilead | 34 | $538 |
| Braeburn Inc. | 13 | $422 |
| Indivior Inc. | 20 | $405 |
| Teva Pharmaceuticals USA, Inc. | 15 | $348 |
| Exact Sciences | 10 | $215 |
| Alkermes, Inc. | 6 | $145 |
| Phathom Pharmaceuticals, Inc. | 8 | $137 |
| Otsuka America Pharmaceutical, Inc. | 1 | $124 |
| Orexo US, Inc. | 4 | $87 |
| Neurocrine Biosciences, Inc. | 4 | $78 |
| Pfizer | 4 | $69 |
| Bardy Diagnostics, Inc. | 2 | $41 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Lundbeck LLC | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Merck | 1 | $16 |
| Advanced Oxygen Therapy Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,928 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $35,086 |
| OzempicSemaglutide | 15 | $13,578 |
| XareltoRivaroxaban | 19 | $12,885 |
| JanuviaSitagliptin Phosphate | 13 | $11,939 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $7,836 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 55 | $7,149 |
| BreynaBudesonide/Formoterol Fumarate | 18 | $2,879 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 96 | $2,670 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,003 |
| Buspirone Hcl | 113 | $1,867 |
| Quetiapine Fumarate | 77 | $1,686 |
| Galantamine Hbr | 12 | $1,678 |
| Atorvastatin Calcium | 176 | $1,458 |
| Gabapentin | 116 | $1,302 |
| Potassium Chloride | 27 | $1,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $69 | $35,08648 claims |
| MerckJanuvia | $16 | $11,93913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Binghamton
- Frank EderBinghamton$46.2M
- Sanjiv PatelBinghamton$41K
- Matthew DavisRochester$76.6M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.